Developer docs
API playgroundTry for free, no card

Search company profiles

Mutabilis

Full company profile

uuid0003e69

Namestring
Mutabilis
Legal namestring
Tamrisa
Websiteurl
mutabilis.fr
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Mutabilis, now operating as Tamrisa, is a French specialty pharmaceutical venture headquartered in Paris with an R&D site at Parc Biocitech in Romainville. Founded in 2001, the company is dedicated to tackling anti-microbial resistance (AMR) along three pillars: innovation, stewardship, and access. Its commercial arm supplies a portfolio of eight long-established, branded antibiotics — including Rovamycine (spiramycin), Oflocet/Monoflocet/Tarivid (ofloxacin), Secnidal (secnidazole), Benambax/Pentacarinat (pentamidine), Triacefan (ceftriaxone), Cefepime Tamrisa, Imipenem Cilastatine Tamrisa, and Meropenem Tamrisa — registered and sold in more than 40 countries through a network of distribution partners and manufacturing counterparties.

Its innovation engine centers on dabocins, a proprietary new class of antibacterials built on the diazabicyclooctane scaffold that uniquely combines Penicillin-Binding Protein inhibition with stability against all four β-lactamase classes (A, B, C, D). Two active programs — TMR010 (formerly EBL-1463) targeting carbapenem-resistant Enterobacterales, and TMR020 targeting carbapenem-resistant Enterobacterales, Pseudomonas and Acinetobacter — are advancing through Lead Optimization/Preclinical/Phase 1 with support from CARB-X, the Novo Holdings REPAIR Impact Fund, and Roche.

The company is co-led by Wandrille Ract-Madoux and Benoît Hennion, with François Moreau serving as Scientific Director. It is privately held, funded by management, industry partners and private shareholders, and employs 11-50 people. The business model blends (i) one-time product/distribution sales of established antibiotics across 40+ countries and (ii) long-cycle R&D, with future licensing/royalty economics dependent on clinical progression of the dabocin pipeline.

Short descriptiontext

Mutabilis (operating as Tamrisa) is a French specialty pharma company that combats anti-microbial resistance by commercializing eight established branded antibiotics in 40+ countries and developing dabocins, a proprietary new class of antibacterials, with two preclinical/Phase 1 programs targeting carbapenem-resistant Gram-negative infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRomainville, France
HQ citystring
Romainville
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-infective drug discovery, anti-microbial resistance, antibiotic pharmaceutical, dabocin antibacterial development, generic antibiotic distribution
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-infective Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Antibiotic product sales
TypeOne Time License
Description

Tamrisa commercializes a portfolio of eight proven antibiotics registered and sold in more than 40 countries through a network of distribution partners. Revenue is generated through product sales of established antibiotics including macrolides, fluoroquinolones, cephalosporins, and carbapenems.

tamrisa.com
2R&D program development
TypeLicensing Royalties
Description

The company develops novel antibiotic candidates (TMR010 and TMR020) for carbapenem-resistant bacterial infections with support from funding partners CARB-X, Novo Holdings REPAIR Impact Fund, and Roche, potentially generating future revenue through licensing or commercialization of new drug candidates.

tamrisa.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Rovamycine
Description

Macrolide antibiotic (spiramycine) used for bacterial infections including respiratory tract infections and toxoplasmosis prevention.

tamrisa.com
+7 more records
Core offering1 text field

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical venture that discovers and develops novel anti-infective drug classes, specifically dabocins targeting carbapenem-resistant Gram-negative infections, while commercializing a portfolio of eight established branded antibiotics across more than 40 countries through distribution partners. The company runs two R&D pipeline programs (TMR010 and TMR020) in preclinical/Phase 1 stages with the support of CARB-X, Novo Holdings REPAIR Impact Fund, and Roche.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Products registered and commercialized in 40+ countries through distribution partners
+1 more record
Product overview1 text field

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical company focused on tackling anti-microbial resistance through innovation, stewardship, and access. The company operates a dual-track model combining a commercial portfolio of established antibiotics with a novel R&D pipeline. The commercial portfolio includes eight branded antibiotics—Rovamycine® (spiramycin), Oflocet®/Monoflocet®/Tarivid® (ofloxacin), Secnidal® (secnidazole), Benambax®/Pentacarinat® (pentamidine isetionate), Triacefan® (ceftriaxone), Cefepime Tamrisa® (cefepime), Imipenem Cilastatine Tamrisa® (imipenem cilastatine), and Meropenem Tamrisa® (meropenem)—registered and commercialized in over 40 countries. The R&D pipeline centers on dabocins, a new class of antibacterials derived from the diazabicyclooctane scaffold, with two active programs (TMR010 and TMR020) in preclinical/Phase 1 development targeting carbapenem-resistant Gram-negative bacterial infections.

Product and service10 records
1Rovamycine (spiramycin)
CategoryCommercial antibiotic (macrolide)
2Oflocet / Monoflocet / Tarivid (ofloxacin)
CategoryCommercial antibiotic (fluoroquinolone)
3Secnidal (secnidazole)
CategoryCommercial antiparasitic / antibacterial agent
4Benambax / Pentacarinat (pentamidine isetionate)
CategoryCommercial antiprotozoal / antifungal
5Triacefan (ceftriaxone)
CategoryCommercial antibiotic (cephalosporin)
6Cefepime Tamrisa (cefepime)
CategoryCommercial antibiotic (cephalosporin)
7Imipenem Cilastatine Tamrisa (imipenem cilastatine)
CategoryCommercial antibiotic (carbapenem combination)
8Meropenem Tamrisa (meropenem)
CategoryCommercial antibiotic (carbapenem)
9TMR010 (i.v.)
CategoryPipeline R&D program (novel dabocin)
10TMR020 (i.v.)
CategoryPipeline R&D program (novel dabocin)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeOthers
Description

Manufacturing partners support the production and supply chain security for the company's portfolio of eight proven antibiotics distributed in 40+ countries.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Iterum is a clinical-stage anti-infectives company developing oral and IV antibiotics against multi-drug resistant pathogens including carbapenem-resistant Enterobacterales, directly comparable to Tamrisa's TMR010/TMR020 programs.

TypeDirect peer
Description

Entasis develops targeted antibacterial therapies for serious drug-resistant infections, including carbapenem-resistant Acinetobacter — overlapping directly with Tamrisa's pipeline focus on WHO priority pathogens.

3Nabriva Therapeutics
TypeDirect peer
Description

Nabriva is a biopharmaceutical company commercializing antibiotics (lefamulin) and developing new anti-infectives, sharing Tamrisa's hybrid model of marketed antibiotics plus innovative R&D pipeline.

TypeDirect peer
Description

Melinta is an antibiotics-focused commercial-stage company with a marketed portfolio of branded antibacterials, mirroring Tamrisa's strategy of coupling established antibiotic sales with stewardship commitments.

TypeDirect peer
Description

Paratek developed and commercialized tetracycline-class antibiotics (omadacycline, sarecycline) for serious community-acquired infections, a comparable small-cap anti-infectives commercial and R&D story.

TypeDirect peer
Description

Tetraphase developed eravacycline for complicated intra-abdominal and urinary tract infections, an antibiotic specialist with comparable scientific depth and AMR focus before its acquisition by La Jolla.

TypeDirect peer
Description

VenatoRx develops novel antibacterial agents, including β-lactam/β-lactamase inhibitor combinations targeting resistant Gram-negative infections, directly overlapping Tamrisa's dabocin scaffold work.

TypeDirect peer
Description

Achaogen developed plazomicin for carbapenem-resistant Enterobacterales, providing a directly comparable commercial-stage AMR antibiotics story before its wind-down.

TypeBroad incumbent
Description

Roche is a global pharmaceutical incumbent that actively backs Tamrisa's pipeline and historically has broader anti-infectives and diagnostic interests relevant to AMR stewardship.

10GSK
TypeBroad incumbent
Description

GSK operates one of the largest anti-infectives franchises globally and pursues novel antibacterial R&D, representing the large-cap comparable for Tamrisa's commercial portfolio and AMR pipeline ambition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mutabilis

Anti-infective Pharmaceuticalsmutabilis.fr

Mutabilis (operating as Tamrisa) is a French specialty pharma company that combats anti-microbial resistance by commercializing eight established branded antibiotics in 40+ countries and developing dabocins, a proprietary new class of antibacterials, with two preclinical/Phase 1 programs targeting carbapenem-resistant Gram-negative infections.

What Mutabilis does

Mutabilis, now operating as Tamrisa, is a French specialty pharmaceutical venture headquartered in Paris with an R&D site at Parc Biocitech in Romainville. Founded in 2001, the company is dedicated to tackling anti-microbial resistance (AMR) along three pillars: innovation, stewardship, and access. Its commercial arm supplies a portfolio of eight long-established, branded antibiotics — including Rovamycine (spiramycin), Oflocet/Monoflocet/Tarivid (ofloxacin), Secnidal (secnidazole), Benambax/Pentacarinat (pentamidine), Triacefan (ceftriaxone), Cefepime Tamrisa, Imipenem Cilastatine Tamrisa, and Meropenem Tamrisa — registered and sold in more than 40 countries through a network of distribution partners and manufacturing counterparties.

Its innovation engine centers on dabocins, a proprietary new class of antibacterials built on the diazabicyclooctane scaffold that uniquely combines Penicillin-Binding Protein inhibition with stability against all four β-lactamase classes (A, B, C, D). Two active programs — TMR010 (formerly EBL-1463) targeting carbapenem-resistant Enterobacterales, and TMR020 targeting carbapenem-resistant Enterobacterales, Pseudomonas and Acinetobacter — are advancing through Lead Optimization/Preclinical/Phase 1 with support from CARB-X, the Novo Holdings REPAIR Impact Fund, and Roche.

The company is co-led by Wandrille Ract-Madoux and Benoît Hennion, with François Moreau serving as Scientific Director. It is privately held, funded by management, industry partners and private shareholders, and employs 11-50 people. The business model blends (i) one-time product/distribution sales of established antibiotics across 40+ countries and (ii) long-cycle R&D, with future licensing/royalty economics dependent on clinical progression of the dabocin pipeline.

Mutabilis firmographics

Firmographics
Name
Mutabilis
Legal name
Tamrisa
Website
https://mutabilis.fr
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Mutabilis (operating as Tamrisa) is a French specialty pharma company that combats anti-microbial resistance by commercializing eight established branded antibiotics in 40+ countries and developing dabocins, a proprietary new class of antibacterials, with two preclinical/Phase 1 programs targeting carbapenem-resistant Gram-negative infections.
Ownership category
akta.pro rank

Mutabilis industry classification

Industry
Product category
Anti-infective Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Anti-infective drug discovery
  • Anti-microbial resistance
  • Antibiotic pharmaceutical
  • Dabocin antibacterial development
  • Generic antibiotic distribution

Where Mutabilis is headquartered

Location

Headquarters

HQ city
Romainville
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Mutabilis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Antibiotic product sales: Tamrisa commercializes a portfolio of eight proven antibiotics registered and sold in more than 40 countries through a network of distribution partners. Revenue is generated through product sales of established antibiotics including macrolides, fluoroquinolones, cephalosporins, and carbapenems.
  2. R&D program development: The company develops novel antibiotic candidates (TMR010 and TMR020) for carbapenem-resistant bacterial infections with support from funding partners CARB-X, Novo Holdings REPAIR Impact Fund, and Roche, potentially generating future revenue through licensing or commercialization of new drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Mutabilis product offering

Product offering

Core offering

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical venture that discovers and develops novel anti-infective drug classes, specifically dabocins targeting carbapenem-resistant Gram-negative infections, while commercializing a portfolio of eight established branded antibiotics across more than 40 countries through distribution partners. The company runs two R&D pipeline programs (TMR010 and TMR020) in preclinical/Phase 1 stages with the support of CARB-X, Novo Holdings REPAIR Impact Fund, and Roche.

Product overview

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical company focused on tackling anti-microbial resistance through innovation, stewardship, and access. The company operates a dual-track model combining a commercial portfolio of established antibiotics with a novel R&D pipeline. The commercial portfolio includes eight branded antibiotics—Rovamycine® (spiramycin), Oflocet®/Monoflocet®/Tarivid® (ofloxacin), Secnidal® (secnidazole), Benambax®/Pentacarinat® (pentamidine isetionate), Triacefan® (ceftriaxone), Cefepime Tamrisa® (cefepime), Imipenem Cilastatine Tamrisa® (imipenem cilastatine), and Meropenem Tamrisa® (meropenem)—registered and commercialized in over 40 countries. The R&D pipeline centers on dabocins, a new class of antibacterials derived from the diazabicyclooctane scaffold, with two active programs (TMR010 and TMR020) in preclinical/Phase 1 development targeting carbapenem-resistant Gram-negative bacterial infections.

Differentiator

Problem solved

Functional benefit

Brands

  • Rovamycine: Macrolide antibiotic (spiramycine) used for bacterial infections including respiratory tract infections and toxoplasmosis prevention.
  • Oflocet / Monoflocet / Tarivid
  • Secnidal
  • Benambax / Pentacarinat
  • Triacefan
  • Cefepime Tamrisa
  • Imipenem Cilastatine Tamrisa
  • Meropenem Tamrisa

Products and services

  • Rovamycine (spiramycin)
  • Oflocet / Monoflocet / Tarivid (ofloxacin)
  • Secnidal (secnidazole)
  • Benambax / Pentacarinat (pentamidine isetionate)
  • Triacefan (ceftriaxone)
  • Cefepime Tamrisa (cefepime)
  • Imipenem Cilastatine Tamrisa (imipenem cilastatine)
  • Meropenem Tamrisa (meropenem)
  • TMR010 (i.v.)
  • TMR020 (i.v.)

Quantifiable outcome

  • Products registered and commercialized in 40+ countries through distribution partners
  • +1 more outcomes

Companies that use Mutabilis

Customer profile

Segments1 record

Ideal customer profiles2 records

Mutabilis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mutabilis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Manufacturing partnerssupportingOthersManufacturing partners support the production and supply chain security for the company's portfolio of eight proven antibiotics distributed in 40+ countries.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Mutabilis competitors and assessment

Company assessment

Direct peers

  • Iterum Therapeutics: Iterum is a clinical-stage anti-infectives company developing oral and IV antibiotics against multi-drug resistant pathogens including carbapenem-resistant Enterobacterales, directly comparable to Tamrisa's TMR010/TMR020 programs.
  • Entasis Therapeutics (Innoviva): Entasis develops targeted antibacterial therapies for serious drug-resistant infections, including carbapenem-resistant Acinetobacter — overlapping directly with Tamrisa's pipeline focus on WHO priority pathogens.
  • Nabriva Therapeutics: Nabriva is a biopharmaceutical company commercializing antibiotics (lefamulin) and developing new anti-infectives, sharing Tamrisa's hybrid model of marketed antibiotics plus innovative R&D pipeline.
  • Melinta Therapeutics: Melinta is an antibiotics-focused commercial-stage company with a marketed portfolio of branded antibacterials, mirroring Tamrisa's strategy of coupling established antibiotic sales with stewardship commitments.
  • Paratek Pharmaceuticals: Paratek developed and commercialized tetracycline-class antibiotics (omadacycline, sarecycline) for serious community-acquired infections, a comparable small-cap anti-infectives commercial and R&D story.
  • Tetraphase Pharmaceuticals: Tetraphase developed eravacycline for complicated intra-abdominal and urinary tract infections, an antibiotic specialist with comparable scientific depth and AMR focus before its acquisition by La Jolla.
  • VenatoRx Pharmaceuticals: VenatoRx develops novel antibacterial agents, including β-lactam/β-lactamase inhibitor combinations targeting resistant Gram-negative infections, directly overlapping Tamrisa's dabocin scaffold work.
  • Achaogen (historical): Achaogen developed plazomicin for carbapenem-resistant Enterobacterales, providing a directly comparable commercial-stage AMR antibiotics story before its wind-down.

Broad incumbents

  • Roche: Roche is a global pharmaceutical incumbent that actively backs Tamrisa's pipeline and historically has broader anti-infectives and diagnostic interests relevant to AMR stewardship.
  • GSK: GSK operates one of the largest anti-infectives franchises globally and pursues novel antibacterial R&D, representing the large-cap comparable for Tamrisa's commercial portfolio and AMR pipeline ambition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Mutabilis social profiles

Digital presence

Mutabilis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mutabilis leadership team

Management profile

Number of profiles

Profiles3 records

Mutabilis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mutabilis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mutabilis

What does Mutabilis do?

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical venture that discovers and develops novel anti-infective drug classes, specifically dabocins targeting carbapenem-resistant Gram-negative infections, while commercializing a portfolio of eight established branded antibiotics across more than 40 countries through distribution partners. The company runs two R&D pipeline programs (TMR010 and TMR020) in preclinical/Phase 1 stages with the support of CARB-X, Novo Holdings REPAIR Impact Fund, and Roche.

Is Mutabilis a public or private company?

Mutabilis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mutabilis founded?

Mutabilis was founded in 2001. It employs 11 to 50 people.

Where is Mutabilis based?

Mutabilis is headquartered in Romainville, France, in the Europe region.

How does Mutabilis make money?

Two revenue lines are on record. Antibiotic product sales are the primary driver. The others are R&D program development.

Who are Mutabilis's main competitors?

Direct peers on record are Iterum Therapeutics, Entasis Therapeutics (Innoviva), Nabriva Therapeutics, Melinta Therapeutics, Paratek Pharmaceuticals, Tetraphase Pharmaceuticals, VenatoRx Pharmaceuticals and Achaogen (historical). Broad incumbents are Roche and GSK.

Does Mutabilis have an API?

No public API is recorded for Mutabilis.

What industry is Mutabilis in?

Mutabilis's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals